# AMIPHARM

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amipharm

- Industry: Pharmaceuticals
- Headquarters: Seongnam, South Korea
- Website: www.amipharm.com/
- Total disclosed funding: $2.7M
- Latest round: Series C (Feb 28, 2025)
- Investors on record: 2

## About

Based in South Korea, AMI Pharm Co., Ltd specializes in developing innovative injectable solutions for targeted fat reduction, focusing on enhancing aesthetic outcomes through non-invasive treatments.AMI Pharm Co., Ltd, founded in 2005, operates from Seongnam, South Korea, and is involved in the production of injectable treatments.
In September 2026,?AMIPHARM raised? KRW 20.5 billion in pre-IPO funding from new investor NH Bank, Korea Investment Value Asset Management, Magna Investment, Hyundai Venture Investment, IBK Capital, Daishin Securities, Hyundai Investment Partners, Samho Green Investment, Dongwon Technology Investment. Other unspecified investors also participated in this round. 
AMIPHARM specializes in the development of scientifically validated and safe injectable solutions for localized fat reduction, primarily focusing on their core product, AYP-101. This injectable treatment utilizes phosphatidylcholine to selectively induce apoptosis (cell death) and lipolysis (fat breakdown) within adipocytes, offering a novel mechanism for reducing localized fat deposits. The company aims to enhance the quality of life for individuals seeking aesthetic improvements without the pain associated with traditional fat reduction methods, such as liposuction or other invasive techniques. AMIPHARM targets various markets globally, serving healthcare providers and aesthetic practitioners who administer these treatments to end users seeking effective and safe body contouring solutions.AMIPHARM generates revenue through the distribution of its flagship product, AYP-101, to healthcare providers and aesthetic clinics that offer fat reduction services. The business model involves direct sales to these medical establishments, allowing practitioners to utilize the product on patients seeking non-invasive fat reduction alternatives. The revenue model supports healthcare providers in delivering effective treatments while ensuring the company’s profitability, although specific pricing details for AYP-101 have not been disclosed.
The company will use the funding to obtain regulatory approval and commercialize its subcutaneous fat reduction injection AYP-101, establish manufacturing capabilities, expand sales and marketing activities, broaden indications to cellulite and other applications, advance next-generation fat reduction injectables, and support global clinical development and overseas market expansion.

## Funding rounds

- Series C, Feb 28, 2025, $2.7M — NAU IB Capital, GSA Private Equity

## Investors

- NAU IB Capital (https://capitalatlas.ai/funds/nau-ib-capital) — Series C
- GSA Private Equity (https://capitalatlas.ai/funds/gsa-private-equity) — Series C